TAFAMIDIS MEGLUMINE 20 mg ORAL CAPSULE [Vyndaqel]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Oral tafamidis (Vyndaqel®) is the first disease-modifying drug approved to delay the progression of peripheral neurological…
: Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid…